TY - JOUR
TI - Long-term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes
AU - Younossi, Z.M.
AU - Stepanova, M.
AU - Younossi, I.
AU - Pan, C.Q.
AU - Janssen, H.L.A.
AU - Papatheodoridis, G.
AU - Nader, F.
JO - Clinical Gastroenterology and Hepatology
PY - 2019
VL - 17
TODO - 8
SP - 1641-1642.e1
PB - W.B. Saunders
SN - 1542-3565, 1542-7714
TODO - 10.1016/j.cgh.2018.09.041
TODO - adefovir;  entecavir;  lamivudine;  telbivudine;  antivirus agent;  virus DNA, adult;  antiviral therapy;  Asian;  female;  hepatitis B;  human;  major clinical study;  male;  mental health;  patient-reported outcome;  physical functioning score;  population research;  presenteeism;  productivity;  scoring system;  Short Form 36;  Short Survey;  United States;  viremia;  chronic hepatitis B;  follow up;  genetics;  Hepatitis B virus;  middle aged;  register;  retrospective study;  time factor;  virology, Antiviral Agents;  DNA, Viral;  Female;  Follow-Up Studies;  Hepatitis B virus;  Hepatitis B, Chronic;  Humans;  Male;  Middle Aged;  Patient Reported Outcome Measures;  Registries;  Retrospective Studies;  Time Factors
TODO - Worldwide, viral hepatitis remains the most common cause of chronic liver disease.1 In this context, hepatitis B virus (HBV) infection and its complications are responsible for a tremendous clinical burden related to cirrhosis and hepatocellular carcinoma.1 In contrast, long-term HBV suppression can improve hepatic fibrosis and clinical outcomes.2 © 2019 AGA Institute
ER -